These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30997479)

  • 1. Empiric Meropenem-based versus Ceftazidime-based Therapy for Severe Community-Acquired Pneumonia in a Retrospective Cohort Study.
    Chua NG; Liew YX; Lee W; Tang SS; Zhou YP; Patel K; Kwa AL; Chlebicki MP
    Ann Acad Med Singap; 2019 Mar; 48(3):98-103. PubMed ID: 30997479
    [No Abstract]   [Full Text] [Related]  

  • 2. Meropenem monotherapy as empiric treatment of nosocomial lower respiratory tract infection.
    Sieger B
    Crit Care Med; 1998 Aug; 26(8):1462-3. PubMed ID: 9710113
    [No Abstract]   [Full Text] [Related]  

  • 3. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime.
    Finch RG; Pemberton K; Gildon KM
    J Chemother; 1998 Feb; 10(1):35-46. PubMed ID: 9531074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for severe community-acquired pneumonia.
    Berk SL
    Clin Infect Dis; 1997 Jul; 25(1):168-9. PubMed ID: 9243063
    [No Abstract]   [Full Text] [Related]  

  • 5. [Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association].
    Strålin K; Goscinski G; Hedlund J; Lidman C; Spindler C; Ortqvist A; Holmberg H
    Lakartidningen; 2008 Sep 17-23; 105(38):2582-7. PubMed ID: 18846863
    [No Abstract]   [Full Text] [Related]  

  • 6. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community-acquired pneumonia.
    Chokshi R; Restrepo MI; Weeratunge N; Frei CR; Anzueto A; Mortensen EM
    Eur J Clin Microbiol Infect Dis; 2007 Jul; 26(7):447-51. PubMed ID: 17534677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
    Piso RJ; Arnold C; Bassetti S
    Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urinary pneumococcal or Legionella antigen detection tests and low-spectrum antibiotic therapy for community-acquired pneumonia].
    Roger PM; Risso K; Hyvernat H; Landraud L; Vassallo M; Dellamonica J; de Salvador F; Cua E; Bernardin G
    Med Mal Infect; 2010 Jun; 40(6):347-51. PubMed ID: 20172672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe pneumonia and a second antibiotic.
    Macfarlane J
    Lancet; 2002 Apr; 359(9313):1170-2. PubMed ID: 11955532
    [No Abstract]   [Full Text] [Related]  

  • 10. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M
    Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of community-acquired pneumonia].
    Ott SR
    MMW Fortschr Med; 2010 Nov; 152(45):38-40. PubMed ID: 21319408
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimal antibiotic treatment in severe pneumococcal pneumonia--time for real answers.
    Waterer GW
    Eur J Clin Microbiol Infect Dis; 2005 Oct; 24(10):691-2. PubMed ID: 16244854
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe Community-acquired Pneumonia Caused by Acinetobacter baumannii Successfully Treated with the Initial Administration of Meropenem Based on the Sputum Gram Staining Findings.
    Iwasawa Y; Hosokawa N; Harada M; Hayano S; Shimizu A; Suzuki D; Nakashima K; Yaegashi M
    Intern Med; 2019 Jan; 58(2):301-305. PubMed ID: 30210104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
    Torres A; Zhong N; Pachl J; Timsit JF; Kollef M; Chen Z; Song J; Taylor D; Laud PJ; Stone GG; Chow JW
    Lancet Infect Dis; 2018 Mar; 18(3):285-295. PubMed ID: 29254862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More on pneumonia: treatment of MRSA in community acquired pneumonia.
    Greig J; Jenks P
    BMJ; 2006 Jun; 332(7553):1334. PubMed ID: 16740574
    [No Abstract]   [Full Text] [Related]  

  • 17. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group.
    Sieger B; Berman SJ; Geckler RW; Farkas SA
    Crit Care Med; 1997 Oct; 25(10):1663-70. PubMed ID: 9377880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of non-nosocomial pneumonia].
    Drömann D; Schaaf B
    MMW Fortschr Med; 2008 Jan; 150(3-4):31-4; quiz 35. PubMed ID: 18326476
    [No Abstract]   [Full Text] [Related]  

  • 19. [Initial empirical antibiotic treatment of community-acquired pneumonia].
    Frías J; Gomis M; Prieto J; Mensa J; Bouza E; García-Rodríguez JA; Torres A; Dorca J; Zalacaín R; García de Lomas J
    Rev Esp Quimioter; 1998 Sep; 11(3):255-61. PubMed ID: 9795313
    [No Abstract]   [Full Text] [Related]  

  • 20. [Management of community-acquired pneumopathies of adults in the city and at the hospital].
    Léophonte P
    Presse Med; 1998 Sep; 27 Suppl 4():5-7. PubMed ID: 9798473
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.